Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Obesity 1Lymphoma, B-Cell 1Lung Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

liposomal doxorubicin 31-dodecylpyridoxal 2pembrolizumab 1mirabegron 1disitamab vedotin 1anlotinib 1Paclitaxel 1Gemcitabine 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Ovarian Cancer Recurrent × mirabegron × Clear all
NCT06791460 2025-03-18

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

Obstetrics & Gynecology Hospital of Fudan University

Phase 2/3 Recruiting
296 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡